Press release
Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to the Company’s Board of Directors, effective January 15, 2020. \n Ms. Tetlow is Managing Partner and Founder of Potrero Hill Advisors. Throughout her career as a serial Chief Financial Officer, Ms. Tetlow has held board seats, served on Audit and Transaction Committees through successful acquisitions, served as the board’s financial expert and has been the CFO of public companies. Dr. Ling is a Professor of Neurology and Attending Neuro Critical Care Physician at Johns Hopkins Medical Institutions and the Emeritus Professor of Neurology, Uniformed Services University of the Health Science. Dr. Ling is an internationally recognized expert in brain health and was the founding Director of the Biological Technologies Office at Defense Advanced Research Projects Agency. Dr. Ling served as an officer in the United States Army Medical Corps for 27 years before retiring as a colonel in 2012. “We are pleased to welcome Dr. Ling and Ms. Tetlow to our Board,” said Augustine Lawlor, Chairman of the Board. “They are both leaders of the highest caliber who bring invaluable experience in areas such as neuroscience, biotechnology, pharmacology, life sciences, operations and finance. We look forward to benefitting from their expertise as we execute on our strategic priorities and create value for our shareholders.” In connection with this announcement, the Company also announced that it has entered into an agreement with JDS1, LLC. As part of the agreement, JDS1, LLC will vote all of its shares in favor of each of the Company’s nominees at the 2020 Annual Meeting of Stockholders and will abide by customary standstill provisions and voting commitments. Jeff Himawan, Ph.D. and John P. Richard will not stand for reelection at the Company’s 2020 Annual Meeting of Stockholders. Additional information about the agreement will be filed with the Securities and Exchange Commission. About Catalyst BiosciencesCatalyst is a clinical-stage biopharmaceutical company which is focused on addressing unmet needs in rare diseases and systemic complement media...